Monitoring Body Composition Change for Intervention Studies with Advancing 3D Optical Imaging Technology in Comparison to Dual-Energy X-Ray Absorptiometry

Abstract

Recent 3D optical (3DO) imaging advancements have provided more accessible, affordable, and self–operating opportunities for assessing body composition. 3DO is accurate and precise with respect to clinical measures made by dual–energy X–ray absorptiometry (DXA). However, the sensitivity for monitoring body composition change over time with 3DO body shape is unknown. Therefore, this study aimed to evaluate 3DO ability to monitor body composition changes across multiple intervention studies. A retrospective analysis was performed using intervention studies on healthy adults that were complimentary to the cross–sectional study, Shape Up! Adults. Each participant received a DXA (Hologic Discovery/A system) and 3DO (Fit3D ProScanner) scan at baseline and follow–up. 3DO meshes were digitally registered and reposed using Meshcapade to standardize the vertices and pose. Each 3DO mesh was transformed into principal components (PCs) using an established statistical shape model. The PCs were used to predict whole–body and regional body composition values using published equations. Body composition changes (follow–up minus baseline) were compared to DXA with linear regression. The analysis included 128 participants (43 females) in six studies. The mean (SD) length of follow-up was 13 (5) weeks, range of 3-23 weeks; change in percent fat was 2.8% (2.1%), with a range of 2.4 – 8.3%. Agreement between 3DO and DXA (R2) for changes in total fat mass (FM), total fat–free mass (FFM), and appendicular lean mass, respectively, were 0.89, 0.77, and 0.69 with RMSEs of 1.78 kg, 1.42 kg, and 0.37 kg in females, and 0.77, 0.76, and 0.46 with RMSEs of 2.28 kg, 1.67 kg, and 0.51 kg in males. Statistical significance of individual changes agreed for both DXA and 3DO in the majority of the sample for total FM (70%) and FFM (81%). Further adjustment with demographic descriptors improved the 3DO change agreement to changes observed with DXA. Compared to DXA, 3DO was highly sensitive in detecting body shape changes over time. The 3DO method was sensitive enough to detect even small changes in body composition during intervention studies. The safety and accessibility of 3DO allow users to self–monitor frequently throughout interventions.

Competing Interest Statement

SBH reports his role on the Medical Advisory Boards of Tanita Corporation, Amgen, and Medifast; he is also an Amazon Scholar.

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT03637855

Funding Statement

Phases of this study were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH R01 DK R01DK109008), National Institute of Aging (5R21AG058181), the US Army Medical Research and Development Command, Military Operational Medicine Research Program Grant W81XWH-19-C-0162. Supported in part by an appointment to the U.S. Army Research Institute of Environmental Medicine administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Army Medical Research and Development Command.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants provided informed consent. The study protocol was approved by the Institutional Review Boards (IRBs) at Pennington Biomedical Research Center (IRB study #2016-053), University of California, San Francisco (IRB #15-18066), and the University of Hawaii Office of Research Compliance (UH ORC, CHS #2017-01018)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

留言 (0)

沒有登入
gif